Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma

Conclusion This post-hoc analysis provides evidence for a dose-response relationship between the administered dose of carfilzomib and efficacy. Teaser We examined the dose-response relationship of the proteasome inhibitor carfilzomib in multiple myeloma patients (n=461) treated in phase II trials using logistic regression models. In the primary analysis, adjustment for covariates yielded an increase in the odds ratio for response for each 1-mg/m² increase in the average administered dose of carfilzomib per patient, which provides evidence for a dose-response relationship.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research